Haemonetics (NYSE: HAE) reported Q4 EPS of $1.24, $0.02 better than the analyst estimate of $1.22. Revenue for the quarter came in at $331 million versus the consensus estimate of $330.66 million.

GUIDANCE:

Haemonetics sees FY2026 EPS of $4.70-$5.00, versus the consensus of $4.54.

For earnings history and earnings-related data on Haemonetics (HAE) click here.